Authors: Bernard, GR Ely, EW Wright, TJ Fraiz, J Stasek, JE Russell, JA Mayers, I Rosenfeld, BA Morris, PE Yan, SB Helterbrand, JD

Citation: Gr. Bernard et al., Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis, CRIT CARE M, 29(11), 2001, pp. 2051-2059

Authors: Bernard, GR Ely, EW Helterbrand, JD

Citation: Gr. Bernard et al., Recombinant human activated protein C for severe sepsis - Reply, N ENG J MED, 345(3), 2001, pp. 220-221

Authors: Bernard, GR Vincent, JL Laterre, P LaRosa, SP Dhainaut, JF Lopez-Rodriguez, A Steingrub, JS Garber, GE Helterbrand, JD Ely, EW Fisher, CJ

Citation: Gr. Bernard et al., Efficacy and safety of recombinant human activated protein C for severe sepsis., N ENG J MED, 344(10), 2001, pp. 699-709

Authors: Yan, SB Helterbrand, JD Hartman, DL Wright, TJ Bernard, GR

Citation: Sb. Yan et al., Low levels of protein C are associated with poor outcome in severe sepsis, CHEST, 120(3), 2001, pp. 915-922

Authors: Mosca, L Barrett-Connor, E Wenger, NK Collins, P Grady, D Kornitzer, M Moscarelli, E Paul, S Wright, TJ Helterbrand, JD Anderson, PW

Citation: L. Mosca et al., Design and methods of the raloxifene use for the heart (RUTH) study, AM J CARD, 88(4), 2001, pp. 392-395